Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by von Bergwelt-Baildon, M.
Right arrow Articles by Gribben, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Bergwelt-Baildon, M.
Right arrow Articles by Gribben, J. G.
Related Collections
Right arrow 2004 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:853-857, 2004
© 2004 European Society for Medical Oncology

CD40 activation: potential for specific immunotherapy in B-CLL

Received 15 August 2003; revised 23 November 2003; accepted 23 December 2003

Despite encouraging scientific and therapeutic advances, chronic lymphocytic leukemia (CLL) principally remains an incurable disease. Allogeneic transplantation represents the only curative approach, but is marked by high mortality. Novel and less toxic treatment modalities are needed. Immunotherapeutic approaches have clearly demonstrated potential effectiveness in CLL and other B-cell malignancies. To successfully direct immunity against CLL, highly immunogenic tumor cells or tumor-antigen-loaded antigen-presenting cells are necessary. The CD40–CD40L interaction has been shown to significantly increase antigen presentation in normal and malignant B-cells. Here we discuss biology and potential therapeutic applications of the CD40-system in CLL.

M. von Bergwelt-Baildon1, B. Maecker1, J. Schultze2 and J. G. Gribben1,*

1 Department of Medical Oncology, Disease Center for Hematologic Neoplasia, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 2 Molecular Tumorbiology and Tumorimmunology, Department for Hematology/Oncology, University of Cologne, Germany

Key words: antigen presentation, CD40, CD154, CLL, immunotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
J. C. Fratantoni, L. Li, L. N. Liu, M. V. Peshwa, M. Brenner, E. Yvon, G. Carrum, and E. Biagi
A Practical Approach for Achieving Clinical Immunotherapy of CLL with hCD40L- and hIL-2-Expressing Autologous Tumor Cells.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 450 - 450.
[Abstract]

Home page
 BloodHome page
C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
Blood, November 15, 2005; 106(10): 3515 - 3523.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.